Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects.
There is no evidence that sublingual selegiline reduces the risk of adverse effects associated with oral selegiline. On the contrary, it has a potential for oral ulceration and stomatitis
D000286:Administration, Sublingual; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D019226:Oral Ulcer / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D012642:Selegiline